Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experienceCoronaVac 2회 투여 후 세 번째 추가 접종을 예약해야 합니까? 단일 센터 경험Article Published on 2022-01-012022-09-11 Journal: Journal of medical virology [Category] SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered age anti-SARS-CoV-2 Anti-spike antibody antibody levels approval booster booster dose Capital CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 determine dose Emergency use evaluate examined had no healthcare healthcare worker Healthcare workers Immunoglobulin Immunoglobulin G immunoglobulin G response Inactivated vaccine Infection intervals investigated men Ministry of Health much higher pandemic participant receiving respiratory SARS-CoV-2 second dose seroconversion rate seronegative severe acute respiratory syndrome Coronavirus single-center the vaccine Turkey vaccination Vaccine was performed were used women [DOI] 10.1002/jmv.27318 PMC 바로가기 [Article Type] Article
Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccinationCOVID-19 감염 또는 예방 접종 후의 혈청 유병률 및 IgG 항체 수준Article Published on 2022-01-012022-09-12 Journal: Infectious diseases (London, England) [Category] 진단, [키워드] 95% confidence interval Abbott SARS-CoV-2 IgG age all age groups antibodies antibody antibody level assumed blood sample COVID-19 COVID-19 infection COVID-19 pandemic cross-sectional study described determine domain Estonia Estonian first dose group IgG IgG antibody individual Infection median age mRNA-vaccine. PCR-confirmed COVID-19 PCR-positive positive Prevalence proportion SARS-CoV-2 SARS-CoV-2 PCR SARS-CoV-2 spike protein selected seronegative seropositive individual Seroprevalence significantly higher tested vaccinated individuals vaccination [DOI] 10.1080/23744235.2021.1974540 PMC 바로가기 [Article Type] Article
Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains스파이크 유도 백신은 돌연변이 균주를 포함하여 강력한 스파이크 특이적 T 세포 반응을 이끌어냅니다.Article Published on 2022-01-012022-09-11 Journal: Cytotherapy [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Alpha antibodies B.1.1.7 coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 variants Critical Donor elicit evaluated Evidence mutant strain Mutation reference strain respiratory response robust SARS-CoV-2 seronegative severe acute respiratory syndrome Coronavirus spike-specific T-cell response strain T cell T cells T-cell Response T-cell responses T-cell responses to coronavirus to define vaccination vaccine response variant variant spike variants [DOI] 10.1016/j.jcyt.2021.07.006 PMC 바로가기 [Article Type] Article
Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations케냐 인구에서 SARS-CoV-2 항체를 검출할 때 수용체 결합 단백질에 대한 총 면역글로불린에 대한 WANTAI ELISA 및 스파이크 단백질에 대한 IgG에 대한 ELISA의 비교 성능Article Published on 2022-01-012022-09-10 Journal: Journal of Clinical Virology [Category] SARS, 진단, 치료기술, [키워드] 95% CI approved assays blood donor Blood donors Characteristics Comparative COVID-19 test cross-sectional survey described detect ELISA gold gold standard house IgG immunoassay Immunoglobulin individuals malaria overall concordance Population positive positive sample Protein Receptor binding SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 PCR sensitivity serology seronegative seropositive Seroprevalence specificity Spike protein the WHO Total immunoglobulin variety widespread [DOI] 10.1016/j.jcv.2021.105061 PMC 바로가기 [Article Type] Article
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19강력한 체액성 및 세포성 면역 반응 및 경증 COVID-19 무증상에서 최소 8개월 후 재감염 위험 낮음Article Published on 2022-01-012022-09-11 Journal: Journal of internal medicine [Category] SARS, 진단, 치료기술, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody Asymptomatic asymptomatic to mild Cell Cellular immune response Chain Reaction Cohort coronavirus COVID-19 COVID-19 disease severity COVID-19 patient COVID-19 patients cumulative cumulative incidence detectable immune response Follow-up HCW healthcare worker hospitalized COVID-19 patients humoral Humoral response immune responses incidence Inclusion Infection initial investigated long-term immunity majority memory T memory T cell Mild PCR PCR-confirmed polymerase chain polymerase chain reaction positive positive individual protective effect reduced risk Reinfection remained respiratory response resulting risk SARS-CoV-2 SARS-COV-2 infection seroconverted seronegative seropositive severe acute respiratory syndrome Coronavirus Severe infection spike IgG Support T cell T cell responses vaccination [DOI] 10.1111/joim.13387 PMC 바로가기 [Article Type] Article
Seroprevalence of SARS-CoV-2 and Risk Assessment Among Healthcare Workers at a Dedicated Tertiary Care COVID-19 Hospital in Delhi, India: A Cohort StudyPreventive Medicine Published on 2021-12-292022-10-31 Journal: Cureus [Category] COVID-19, [키워드] adjusted age Analysis antibody assessment association baseline blood sample Care Characteristics Cohort Control COVID-19 cumulative determine disease transmission Follow-up Government HCW HCWs healthcare worker high risk higher risk hospital identify incidence India Infection Infection prevention information measure Measures Nurse participant prevention prospective observational cohort Protective reduced Result risk factor SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 transmission Seroconversion seronegative Seroprevalence Sex smoking status statistically significant Tertiary was collected worker [DOI] 10.7759/cureus.20805 PMC 바로가기 [Article Type] Preventive Medicine
Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infectionArticle Published on 2021-12-222022-10-30 Journal: Nature Immunology [Category] COVID-19, Fulltext, SARS, [키워드] Adaptive immunity Adults antibody Antibody Response Asymptomatic Beta biological basis cellular immunity cellular response children comparable cross-reactive Delta develop generally mild generate help immune response Infection Infectious diseases neutralize occur occurred outcome pediatric regimens response responses against retained robust S2 domain SARS-CoV-2 SARS-COV-2 infection seasonal coronaviruses Seroconversion seronegative specificity Spike protein sustained T cell response the spike protein vaccination variants viral infection viral variant [DOI] 10.1038/s41590-021-01089-8 PMC 바로가기 [Article Type] Article
Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult PopulationArticle Published on 2021-12-172022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-S IgG anti-spike antibodies blood sample BNT162b2 mRNA Cohort collected conducted detectable develop dose enrolled group higher risk identify Infection Italian Italy large cohort messenger Messenger RNA vaccine Neutralizing Neutralizing antibodies Neutralizing antibody response Population Prospective Study recipients response RNA SARS-CoV-2 Seroconversion seronegative seropositive subject subjects tested vaccination Vaccine vaccine dose vaccine-induced antibody [DOI] 10.3390/vaccines9121494 PMC 바로가기 [Article Type] Article
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumoniaCOVID-19 폐렴으로 입원한 개인을 위한 회복기 혈장의 무작위 대조 연구Randomized Controlled Trial Published on 2021-12-152022-09-12 Journal: The Journal of Clinical Investigation [Category] SARS, 임상, 진단, [키워드] 28-day mortality Adaptive immunity Administered adults hospitalized anti-SARS-CoV-2 anti-SARS-CoV-2 antibody benefit CCP clinical clinical severity score clinical trials Comorbidities convalescent plasma COVID-19 disease Efficacy enrolled Evidence Hospitalization Hospitalized hospitalized patient Immunosuppression include individual interquartile range majority mechanical ventilation median outcome measure Oxygenation participant performed Pneumonia populations primary efficacy endpoint Randomized randomized controlled study randomized trial Result risk factor Safe SARS-CoV-2 RNA secondary outcome seronegative seronegative participant severe COVID-19 shown standard care Symptom those with comorbidity treated Treatment Trial WHO with COVID-19 [DOI] 10.1172/JCI155114 PMC 바로가기 [Article Type] Randomized Controlled Trial
Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study2021 년 6 월 ~ 7 월 인도의 일반 인구 및 의료 종사자들 사이에서 SARS-COV-2에 대한 IgG 항체의 혈청 유병률 : 인구 기반 단면 연구Research Article Published on 2021-12-102022-09-10 Journal: PLoS Medicine [Category] SARS, 진단, 치료법, [키워드] 95% CI 95% CIs accelerate Adults age anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody chemiluminescence immunoassay Cluster conducted country Coverage COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional cross-sectional study detectable District dose eligible female General population HCW HCWs Health health facilities healthcare healthcare worker Healthcare workers IgG antibodies IgG antibody include increase in India indicated individual individuals limitation National not different nucleocapsid protein participant participated Participation Population size presence of antibody Prevalence Probability public health researcher rural areas SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody second wave selected seronegative Seroprevalence Serosurvey Serosurveys serum sample serum samples significantly higher tested the District urban areas Vaccination strategy vaccine dose [DOI] 10.1371/journal.pmed.1003877 PMC 바로가기 [Article Type] Research Article